Want to see MANE full AI Analyst Report?
MANE Stock Chart & Stats
$76.29
--
Market closed
$76.29
--
Day’s Range― - ―
52-Week Range$32.00 - $131.24
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
$4.58B
Enterprise Value$3.67B
Total Cash (Recent Filing)$390.80M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.51
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding41,778,687
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-10.94
Price to Sales (P/S)0.00
P/FCF Ratio-18.49
Enterprise Value/Market Cap0.80
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-75.59
Forecast
1Y Price Target
$169.20Price Target Upside121.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Positive Phase 2/3 Efficacy And Safety DataDemonstrated statistical efficacy and a favorable safety profile in a randomized Phase 2/3 cohort is durable proof-of-concept. This materially de-risks the clinical program, strengthens regulatory discussions, and improves prospects for partnerships, payer planning, and commercial development if replicated.
Recent Capital Raise Strengthens RunwayA sizable equity offering plus a $30M pre-funded-warrant placement meaningfully extends cash runway to fund pivotal trials and operations. This reduces immediate financing pressure, supports execution of regulatory milestones, and gives management time to advance registration work and commercial planning.
Comprehensive Late-stage Program Targeting Large MarketA broad, registration-directed development program across male and female populations increases the odds of achieving an approved, commercially meaningful product. If approved, being first-in-class non-hormonal oral therapy could create durable market leadership and address sizable unmet demand in aesthetics.
Bears Say
Pre-revenue With Accelerating Losses And Cash BurnThe company generates no revenue and exhibited sharply widening losses and accelerating cash outflows, meaning operations depend on external funding. This persistent negative cash profile elevates dilution risk, constrains long-term planning, and pressures execution if financing conditions tighten.
Deeply Negative Equity Weakens Financial FlexibilityA sharp swing to negative shareholders' equity undermines solvency metrics despite low reported debt. Negative net worth can constrain access to non-dilutive funding, increase covenant scrutiny, and heighten dependence on equity raises, raising medium-term financing and execution risk.
Program Outcome Dependent On Ongoing Pivotal TrialsCommercial prospects hinge on replicating Part A results in ongoing pivotal trials. This binary clinical/regulatory dependency is structural: failed or inconclusive pivotal readouts would materially impair FDA approval chances and erase anticipated market opportunity and partner interest.
MANE FAQ
What was Veradermics, Incorporated’s price range in the past 12 months?
Veradermics, Incorporated lowest stock price was $32.00 and its highest was $131.24 in the past 12 months.
What is Veradermics, Incorporated’s market cap?
Veradermics, Incorporated’s market cap is $4.58B.
When is Veradermics, Incorporated’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Veradermics, Incorporated’s earnings last quarter?
Currently, no data Available
Is Veradermics, Incorporated overvalued?
According to Wall Street analysts Veradermics, Incorporated’s price is currently Undervalued.
Does Veradermics, Incorporated pay dividends?
Veradermics, Incorporated does not currently pay dividends.
What is Veradermics, Incorporated’s EPS estimate?
Veradermics, Incorporated’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Veradermics, Incorporated have?
Veradermics, Incorporated has 41,778,687 shares outstanding.
What happened to Veradermics, Incorporated’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Veradermics, Incorporated?
Currently, no hedge funds are holding shares in MANE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Veradermics, Incorporated Stock Smart Score
Company Description
Veradermics, Incorporated
Veradermics, Incorporated functions as a biopharmaceutical enterprise focused on devising pioneering therapeutic interventions for various skin and cosmetic disorders. The company's development pipeline includes treatments for Pattern Hair Loss (PHL), impacting both adult and pediatric demographics. A flagship offering is VDPHL01, an orally administered, non-hormonal medication specifically for chronic hair loss management in both male and female patients with PHL. Furthermore, Veradermics is progressing with VDMN, an innovative dissolvable microarray patch technology employing immunotherapy for common warts. Its research also extends to VDAA for addressing alopecia areata, and VDMC, aimed at molluscum contagiosum. Collectively, the firm's product candidates target conditions such as androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. Veradermics caters to healthcare practitioners and clinicians specializing in dermatologic and aesthetic care for patients of all ages, in addition to the wider medical and scientific community engaged in dermatology. Founded in 2019, the company is based in New Haven, Connecticut.
MANE Stock 12 Month Forecast
Average Price Target
$169.20
▲(121.79% Upside)
Vericel
―
Veracyte
―
Kiniksa Pharmaceuticals
―
Arcutis Biotherapeutics
―
Caris Life Sciences, Inc.
―
Ownership Overview
18.55% Insiders
1.03% Mutual Funds
<0.01% Other Institutional Investors
74.55% Public Companies and
Individual Investors